Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.

Abstract excerpt

Acute myeloid leukemia has recently undergone a significant transition into identifying and successfully inhibiting driver mutations leading to disease. One of the most common mutations in acute myeloid leukemia involves the protein FMS-like tyrosine kinase 3 (FLT3), which leads to ligand-independent activation of intracellular signaling cascades leading to the survival and proliferation of the acute leukemia...

Topics

• Aniline Compounds
• Humans
• Leukemia, Myeloid, Acute
• Mutation
• Protein Kinase Inhibitors
• Pyrazines
• fms-Like Tyrosine Kinase 3